



Sen. Jacqueline Y. Collins

Filed: 5/1/2018

10000SB2341sam001

LRB100 17957 JWD 39529 a

1 AMENDMENT TO SENATE BILL 2341

2 AMENDMENT NO. _____. Amend Senate Bill 2341

3 "Section 5. The Illinois Controlled Substances Act is
4 amended by changing Sections 102 and 204 as follows:

5 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

6 Sec. 102. Definitions. As used in this Act, unless the
7 context otherwise requires:

8 (a) "Addict" means any person who habitually uses any drug,
9 chemical, substance or dangerous drug other than alcohol so as
10 to endanger the public morals, health, safety or welfare or who
11 is so far addicted to the use of a dangerous drug or controlled
12 substance other than alcohol as to have lost the power of self
13 control with reference to his or her addiction.

14 (b) "Administer" means the direct application of a
15 controlled substance, whether by injection, inhalation,
16 ingestion, or any other means, to the body of a patient,

1 research subject, or animal (as defined by the Humane
2 Euthanasia in Animal Shelters Act) by:

3 (1) a practitioner (or, in his or her presence, by his
4 or her authorized agent),

5 (2) the patient or research subject pursuant to an
6 order, or

7 (3) a euthanasia technician as defined by the Humane
8 Euthanasia in Animal Shelters Act.

9 (c) "Agent" means an authorized person who acts on behalf
10 of or at the direction of a manufacturer, distributor,
11 dispenser, prescriber, or practitioner. It does not include a
12 common or contract carrier, public warehouseman or employee of
13 the carrier or warehouseman.

14 (c-1) "Anabolic Steroids" means any drug or hormonal
15 substance, chemically and pharmacologically related to
16 testosterone (other than estrogens, progestins,
17 corticosteroids, and dehydroepiandrosterone), and includes:

18 (i) 3[beta],17-dihydroxy-5a-androstane,

19 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,

20 (iii) 5[alpha]-androstan-3,17-dione,

21 (iv) 1-androstenediol (3[beta],

22 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

23 (v) 1-androstenediol (3[alpha],

24 17[beta]-dihydroxy-5[alpha]-androst-1-ene),

25 (vi) 4-androstenediol

26 (3[beta],17[beta]-dihydroxy-androst-4-ene),

(vii) 5-androstenediol
(3[beta],17[beta]-dihydroxy-androst-5-ene),
(viii) 1-androstenedione
([5alpha]-androst-1-en-3,17-dione),
(ix) 4-androstenedione
(androst-4-en-3,17-dione),
(x) 5-androstenedione
(androst-5-en-3,17-dione),
(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xii) boldenone (17[beta]-hydroxyandrost-
1,4,-diene-3-one),
(xiii) boldione (androsta-1,4-
diene-3,17-dione),
(xiv) calusterone (7[beta],17[alpha]-dimethyl-17
[beta]-hydroxyandrost-4-en-3-one),
(xv) clostebol (4-chloro-17[beta]-
hydroxyandrost-4-en-3-one),
(xvi) dehydrochloromethyltestosterone (4-chloro-
17[beta]-hydroxy-17[alpha]-methyl-
androst-1,4-dien-3-one),
(xvii) desoxymethyltestosterone
(17[alpha]-methyl-5[alpha]
-androst-2-en-17[beta]-ol) (a.k.a., madol),
(xviii) [delta]1-dihydrotestosterone (a.k.a.
'1-testosterone') (17[beta]-hydroxy-

1 5[alpha]-androst-1-en-3-one),
2 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-
3 androstan-3-one),
4 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-
5 5[alpha]-androstan-3-one),
6 (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-
7 hydroxyestr-4-ene),
8 (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-
9 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),
10 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],
11 17[beta]-dihydroxyandrost-1,4-dien-3-one),
12 (xxiv) furazabol (17[alpha]-methyl-17[beta]-
13 hydroxyandrostando[2,3-c]-furazan),
14 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,→
15 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-
16 androst-4-en-3-one),
17 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-
18 dihydroxy-estr-4-en-3-one),
19 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-
20 hydroxy-5-androstan-3-one),
21 (xxix) mesterolone (1αmethyl-17[beta]-hydroxy-
22 [5α]-androstan-3-one),
23 (xxx) methandienone (17[alpha]-methyl-17[beta]-
24 hydroxyandrost-1,4-dien-3-one),
25 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-
26 dihydroxyandrost-5-ene),

(xxxii) methenolone (1-methyl-17[beta]-hydroxy-
5[alpha]-androst-1-en-3-one),
(xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-
dihydroxy-5a-androstane),
(xxxiv) 17[alpha]-methyl-3[alpha], 17[beta]-dihydroxy
-5a-androstane),
(xxxv) 17[alpha]-methyl-3[beta], 17[beta]-
dihydroxyandrost-4-ene),
(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-
methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),
(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9(10)-dien-3-one),
(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-
hydroxyestra-4,9-11-trien-3-one),
(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-
hydroxyandrost-4-en-3-one),
(xl) mibolerone (7[alpha], 17a-dimethyl-17[beta]-
hydroxyestr-4-en-3-one),
(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone
(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-
androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-
1-testosterone'),
(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),
(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-
dihydroxyestr-4-ene),
(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-

1 dihydroxyestr-4-ene),
2 (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-
3 dihydroxyestr-5-ene),
4 (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-
5 dihydroxyestr-5-ene),
6 (xlvii) 19-nor-4,9(10)-androstadienedione
7 (estra-4,9(10)-diene-3,17-dione),
8 (xlviii) 19-nor-4-androstenedione (estr-4-
9 en-3,17-dione),
10 (xlix) 19-nor-5-androstenedione (estr-5-
11 en-3,17-dione),
12 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-
13 hydroxygon-4-en-3-one),
14 (li) norclostebol (4-chloro-17[beta]-
15 hydroxyestr-4-en-3-one),
16 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-
17 hydroxyestr-4-en-3-one),
18 (liii) normethandrolone (17[alpha]-methyl-17[beta]-
19 hydroxyestr-4-en-3-one),
20 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-
21 2-oxa-5[alpha]-androstan-3-one),
22 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-
23 dihydroxyandrost-4-en-3-one),
24 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-
25 17[beta]-hydroxy-(5[alpha]-androstan-3-one),
26 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-

1 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),
2 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-
3 (5[alpha]-androst-1-en-3-one),
4 (lix) testolactone (13-hydroxy-3-oxo-13,17-
5 secoandrosta-1,4-dien-17-oic
6 acid lactone),
7 (lx) testosterone (17[beta]-hydroxyandrost-
8 4-en-3-one),
9 (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-
10 diethyl-17[beta]-hydroxygon-
11 4,9,11-trien-3-one),
12 (lxii) trenbolone (17[beta]-hydroxyestr-4,9,
13 11-trien-3-one).

14 Any person who is otherwise lawfully in possession of an
15 anabolic steroid, or who otherwise lawfully manufactures,
16 distributes, dispenses, delivers, or possesses with intent to
17 deliver an anabolic steroid, which anabolic steroid is
18 expressly intended for and lawfully allowed to be administered
19 through implants to livestock or other nonhuman species, and
20 which is approved by the Secretary of Health and Human Services
21 for such administration, and which the person intends to
22 administer or have administered through such implants, shall
23 not be considered to be in unauthorized possession or to
24 unlawfully manufacture, distribute, dispense, deliver, or
25 possess with intent to deliver such anabolic steroid for
26 purposes of this Act.

1 (d) "Administration" means the Drug Enforcement
2 Administration, United States Department of Justice, or its
3 successor agency.

4 (d-5) "Clinical Director, Prescription Monitoring Program"
5 means a Department of Human Services administrative employee
6 licensed to either prescribe or dispense controlled substances
7 who shall run the clinical aspects of the Department of Human
8 Services Prescription Monitoring Program and its Prescription
9 Information Library.

10 (d-10) "Compounding" means the preparation and mixing of
11 components, excluding flavorings, (1) as the result of a
12 prescriber's prescription drug order or initiative based on the
13 prescriber-patient-pharmacist relationship in the course of
14 professional practice or (2) for the purpose of, or incident
15 to, research, teaching, or chemical analysis and not for sale
16 or dispensing. "Compounding" includes the preparation of drugs
17 or devices in anticipation of receiving prescription drug
18 orders based on routine, regularly observed dispensing
19 patterns. Commercially available products may be compounded
20 for dispensing to individual patients only if both of the
21 following conditions are met: (i) the commercial product is not
22 reasonably available from normal distribution channels in a
23 timely manner to meet the patient's needs and (ii) the
24 prescribing practitioner has requested that the drug be
25 compounded.

26 (e) "Control" means to add a drug or other substance, or

1 immediate precursor, to a Schedule whether by transfer from
2 another Schedule or otherwise.

3 (f) "Controlled Substance" means (i) a drug, substance,
4 immediate precursor, or synthetic drug in the Schedules of
5 Article II of this Act or (ii) a drug or other substance, or
6 immediate precursor, designated as a controlled substance by
7 the Department through administrative rule. The term does not
8 include distilled spirits, wine, malt beverages, or tobacco, as
9 those terms are defined or used in the Liquor Control Act of
10 1934 and the Tobacco Products Tax Act of 1995.

11 (f-5) "Controlled substance analog" means a substance:

12 (1) the chemical structure of which is substantially
13 similar to the chemical structure of a controlled substance
14 in Schedule I or II;

15 (2) which has a stimulant, depressant, or
16 hallucinogenic effect on the central nervous system that is
17 substantially similar to or greater than the stimulant,
18 depressant, or hallucinogenic effect on the central
19 nervous system of a controlled substance in Schedule I or
20 II; or

21 (3) with respect to a particular person, which such
22 person represents or intends to have a stimulant,
23 depressant, or hallucinogenic effect on the central
24 nervous system that is substantially similar to or greater
25 than the stimulant, depressant, or hallucinogenic effect
26 on the central nervous system of a controlled substance in

1 Schedule I or II.

2 (g) "Counterfeit substance" means a controlled substance,
3 which, or the container or labeling of which, without
4 authorization bears the trademark, trade name, or other
5 identifying mark, imprint, number or device, or any likeness
6 thereof, of a manufacturer, distributor, or dispenser other
7 than the person who in fact manufactured, distributed, or
8 dispensed the substance.

9 (h) "Deliver" or "delivery" means the actual, constructive
10 or attempted transfer of possession of a controlled substance,
11 with or without consideration, whether or not there is an
12 agency relationship.

13 (i) "Department" means the Illinois Department of Human
14 Services (as successor to the Department of Alcoholism and
15 Substance Abuse) or its successor agency.

16 (j) (Blank).

17 (k) "Department of Corrections" means the Department of
18 Corrections of the State of Illinois or its successor agency.

19 (l) "Department of Financial and Professional Regulation"
20 means the Department of Financial and Professional Regulation
21 of the State of Illinois or its successor agency.

22 (m) "Depressant" means any drug that (i) causes an overall
23 depression of central nervous system functions, (ii) causes
24 impaired consciousness and awareness, and (iii) can be
25 habit-forming or lead to a substance abuse problem, including
26 but not limited to alcohol, cannabis and its active principles

1 and their analogs, benzodiazepines and their analogs,
2 barbiturates and their analogs, opioids (natural and
3 synthetic) and their analogs, and chloral hydrate and similar
4 sedative hypnotics.

5 (n) (Blank).

6 (o) "Director" means the Director of the Illinois State
7 Police or his or her designated agents.

8 (p) "Dispense" means to deliver a controlled substance to
9 an ultimate user or research subject by or pursuant to the
10 lawful order of a prescriber, including the prescribing,
11 administering, packaging, labeling, or compounding necessary
12 to prepare the substance for that delivery.

13 (q) "Dispenser" means a practitioner who dispenses.

14 (r) "Distribute" means to deliver, other than by
15 administering or dispensing, a controlled substance.

16 (s) "Distributor" means a person who distributes.

17 (t) "Drug" means (1) substances recognized as drugs in the
18 official United States Pharmacopoeia, Official Homeopathic
19 Pharmacopoeia of the United States, or official National
20 Formulary, or any supplement to any of them; (2) substances
21 intended for use in diagnosis, cure, mitigation, treatment, or
22 prevention of disease in man or animals; (3) substances (other
23 than food) intended to affect the structure of any function of
24 the body of man or animals and (4) substances intended for use
25 as a component of any article specified in clause (1), (2), or
26 (3) of this subsection. It does not include devices or their

1 components, parts, or accessories.

2 (t-3) "Electronic health record" or "EHR" means an
3 electronic record of health-related information on an
4 individual that is created, gathered, managed, and consulted by
5 authorized health care clinicians and staff.

6 (t-4) "Emergency medical services personnel" has the
7 meaning ascribed to it in the Emergency Medical Services (EMS)
8 Systems Act.

9 (t-5) "Euthanasia agency" means an entity certified by the
10 Department of Financial and Professional Regulation for the
11 purpose of animal euthanasia that holds an animal control
12 facility license or animal shelter license under the Animal
13 Welfare Act. A euthanasia agency is authorized to purchase,
14 store, possess, and utilize Schedule II nonnarcotic and
15 Schedule III nonnarcotic drugs for the sole purpose of animal
16 euthanasia.

17 (t-10) "Euthanasia drugs" means Schedule II or Schedule III
18 substances (nonnarcotic controlled substances) that are used
19 by a euthanasia agency for the purpose of animal euthanasia.

20 (u) "Good faith" means the prescribing or dispensing of a
21 controlled substance by a practitioner in the regular course of
22 professional treatment to or for any person who is under his or
23 her treatment for a pathology or condition other than that
24 individual's physical or psychological dependence upon or
25 addiction to a controlled substance, except as provided herein:
26 and application of the term to a pharmacist shall mean the

1 dispensing of a controlled substance pursuant to the
2 prescriber's order which in the professional judgment of the
3 pharmacist is lawful. The pharmacist shall be guided by
4 accepted professional standards including, but not limited to
5 the following, in making the judgment:

6 (1) lack of consistency of prescriber-patient
7 relationship,

8 (2) frequency of prescriptions for same drug by one
9 prescriber for large numbers of patients,

10 (3) quantities beyond those normally prescribed,

11 (4) unusual dosages (recognizing that there may be
12 clinical circumstances where more or less than the usual
13 dose may be used legitimately),

14 (5) unusual geographic distances between patient,
15 pharmacist and prescriber,

16 (6) consistent prescribing of habit-forming drugs.

17 (u-0.5) "Hallucinogen" means a drug that causes markedly
18 altered sensory perception leading to hallucinations of any
19 type.

20 (u-1) "Home infusion services" means services provided by a
21 pharmacy in compounding solutions for direct administration to
22 a patient in a private residence, long-term care facility, or
23 hospice setting by means of parenteral, intravenous,
24 intramuscular, subcutaneous, or intraspinal infusion.

25 (u-5) "Illinois State Police" means the State Police of the
26 State of Illinois, or its successor agency.

1 (v) "Immediate precursor" means a substance:

2 (1) which the Department has found to be and by rule
3 designated as being a principal compound used, or produced
4 primarily for use, in the manufacture of a controlled
5 substance;

6 (2) which is an immediate chemical intermediary used or
7 likely to be used in the manufacture of such controlled
8 substance; and

9 (3) the control of which is necessary to prevent,
10 curtail or limit the manufacture of such controlled
11 substance.

12 (w) "Instructional activities" means the acts of teaching,
13 educating or instructing by practitioners using controlled
14 substances within educational facilities approved by the State
15 Board of Education or its successor agency.

16 (x) "Local authorities" means a duly organized State,
17 County or Municipal peace unit or police force.

18 (y) "Look-alike substance" means a substance, other than a
19 controlled substance which (1) by overall dosage unit
20 appearance, including shape, color, size, markings or lack
21 thereof, taste, consistency, or any other identifying physical
22 characteristic of the substance, would lead a reasonable person
23 to believe that the substance is a controlled substance, or (2)
24 is expressly or impliedly represented to be a controlled
25 substance or is distributed under circumstances which would
26 lead a reasonable person to believe that the substance is a

1 controlled substance. For the purpose of determining whether
2 the representations made or the circumstances of the
3 distribution would lead a reasonable person to believe the
4 substance to be a controlled substance under this clause (2) of
5 subsection (y), the court or other authority may consider the
6 following factors in addition to any other factor that may be
7 relevant:

8 (a) statements made by the owner or person in control
9 of the substance concerning its nature, use or effect;

10 (b) statements made to the buyer or recipient that the
11 substance may be resold for profit;

12 (c) whether the substance is packaged in a manner
13 normally used for the illegal distribution of controlled
14 substances;

15 (d) whether the distribution or attempted distribution
16 included an exchange of or demand for money or other
17 property as consideration, and whether the amount of the
18 consideration was substantially greater than the
19 reasonable retail market value of the substance.

20 Clause (1) of this subsection (y) shall not apply to a
21 noncontrolled substance in its finished dosage form that was
22 initially introduced into commerce prior to the initial
23 introduction into commerce of a controlled substance in its
24 finished dosage form which it may substantially resemble.

25 Nothing in this subsection (y) prohibits the dispensing or
26 distributing of noncontrolled substances by persons authorized

1 to dispense and distribute controlled substances under this
2 Act, provided that such action would be deemed to be carried
3 out in good faith under subsection (u) if the substances
4 involved were controlled substances.

5 Nothing in this subsection (y) or in this Act prohibits the
6 manufacture, preparation, propagation, compounding,
7 processing, packaging, advertising or distribution of a drug or
8 drugs by any person registered pursuant to Section 510 of the
9 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

10 (y-1) "Mail-order pharmacy" means a pharmacy that is
11 located in a state of the United States that delivers,
12 dispenses or distributes, through the United States Postal
13 Service or other common carrier, to Illinois residents, any
14 substance which requires a prescription.

15 (z) "Manufacture" means the production, preparation,
16 propagation, compounding, conversion or processing of a
17 controlled substance other than methamphetamine, either
18 directly or indirectly, by extraction from substances of
19 natural origin, or independently by means of chemical
20 synthesis, or by a combination of extraction and chemical
21 synthesis, and includes any packaging or repackaging of the
22 substance or labeling of its container, except that this term
23 does not include:

24 (1) by an ultimate user, the preparation or compounding
25 of a controlled substance for his or her own use; or

26 (2) by a practitioner, or his or her authorized agent

1 under his or her supervision, the preparation,
2 compounding, packaging, or labeling of a controlled
3 substance:

4 (a) as an incident to his or her administering or
5 dispensing of a controlled substance in the course of
6 his or her professional practice; or

7 (b) as an incident to lawful research, teaching or
8 chemical analysis and not for sale.

9 (z-1) (Blank).

10 (z-5) "Medication shopping" means the conduct prohibited
11 under subsection (a) of Section 314.5 of this Act.

12 (z-10) "Mid-level practitioner" means (i) a physician
13 assistant who has been delegated authority to prescribe through
14 a written delegation of authority by a physician licensed to
15 practice medicine in all of its branches, in accordance with
16 Section 7.5 of the Physician Assistant Practice Act of 1987,
17 (ii) an advanced practice registered nurse who has been
18 delegated authority to prescribe through a written delegation
19 of authority by a physician licensed to practice medicine in
20 all of its branches or by a podiatric physician, in accordance
21 with Section 65-40 of the Nurse Practice Act, (iii) an advanced
22 practice registered nurse certified as a nurse practitioner,
23 nurse midwife, or clinical nurse specialist who has been
24 granted authority to prescribe by a hospital affiliate in
25 accordance with Section 65-45 of the Nurse Practice Act, (iv)
26 an animal euthanasia agency, or (v) a prescribing psychologist.

1 (aa) "Narcotic drug" means any of the following, whether
2 produced directly or indirectly by extraction from substances
3 of vegetable origin, or independently by means of chemical
4 synthesis, or by a combination of extraction and chemical
5 synthesis:

6 (1) opium, opiates, derivatives of opium and opiates,
7 including their isomers, esters, ethers, salts, and salts
8 of isomers, esters, and ethers, whenever the existence of
9 such isomers, esters, ethers, and salts is possible within
10 the specific chemical designation; however the term
11 "narcotic drug" does not include the isoquinoline
12 alkaloids of opium;

13 (2) (blank);

14 (3) opium poppy and poppy straw;

15 (4) coca leaves, except coca leaves and extracts of
16 coca leaves from which substantially all of the cocaine and
17 ecgonine, and their isomers, derivatives and salts, have
18 been removed;

19 (5) cocaine, its salts, optical and geometric isomers,
20 and salts of isomers;

21 (6) ecgonine, its derivatives, their salts, isomers,
22 and salts of isomers;

23 (7) any compound, mixture, or preparation which
24 contains any quantity of any of the substances referred to
25 in subparagraphs (1) through (6).

26 (bb) "Nurse" means a registered nurse licensed under the

1 Nurse Practice Act.

2 (cc) (Blank).

3 (dd) "Opiate" means any substance having an addiction
4 forming or addiction sustaining liability similar to morphine
5 or being capable of conversion into a drug having addiction
6 forming or addiction sustaining liability.

7 (ee) "Opium poppy" means the plant of the species *Papaver*
8 *somniferum* L., except its seeds.

9 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
10 solution or other liquid form of medication intended for
11 administration by mouth, but the term does not include a form
12 of medication intended for buccal, sublingual, or transmucosal
13 administration.

14 (ff) "Parole and Pardon Board" means the Parole and Pardon
15 Board of the State of Illinois or its successor agency.

16 (gg) "Person" means any individual, corporation,
17 mail-order pharmacy, government or governmental subdivision or
18 agency, business trust, estate, trust, partnership or
19 association, or any other entity.

20 (hh) "Pharmacist" means any person who holds a license or
21 certificate of registration as a registered pharmacist, a local
22 registered pharmacist or a registered assistant pharmacist
23 under the Pharmacy Practice Act.

24 (ii) "Pharmacy" means any store, ship or other place in
25 which pharmacy is authorized to be practiced under the Pharmacy
26 Practice Act.

1 (ii-5) "Pharmacy shopping" means the conduct prohibited
2 under subsection (b) of Section 314.5 of this Act.

3 (ii-10) "Physician" (except when the context otherwise
4 requires) means a person licensed to practice medicine in all
5 of its branches.

6 (jj) "Poppy straw" means all parts, except the seeds, of
7 the opium poppy, after mowing.

8 (kk) "Practitioner" means a physician licensed to practice
9 medicine in all its branches, dentist, optometrist, podiatric
10 physician, veterinarian, scientific investigator, pharmacist,
11 physician assistant, advanced practice registered nurse,
12 licensed practical nurse, registered nurse, emergency medical
13 services personnel, hospital, laboratory, or pharmacy, or
14 other person licensed, registered, or otherwise lawfully
15 permitted by the United States or this State to distribute,
16 dispense, conduct research with respect to, administer or use
17 in teaching or chemical analysis, a controlled substance in the
18 course of professional practice or research.

19 (ll) "Pre-printed prescription" means a written
20 prescription upon which the designated drug has been indicated
21 prior to the time of issuance; the term does not mean a written
22 prescription that is individually generated by machine or
23 computer in the prescriber's office.

24 (mm) "Prescriber" means a physician licensed to practice
25 medicine in all its branches, dentist, optometrist,
26 prescribing psychologist licensed under Section 4.2 of the

1 Clinical Psychologist Licensing Act with prescriptive
2 authority delegated under Section 4.3 of the Clinical
3 Psychologist Licensing Act, podiatric physician, or
4 veterinarian who issues a prescription, a physician assistant
5 who issues a prescription for a controlled substance in
6 accordance with Section 303.05, a written delegation, and a
7 written collaborative agreement required under Section 7.5 of
8 the Physician Assistant Practice Act of 1987, an advanced
9 practice registered nurse with prescriptive authority
10 delegated under Section 65-40 of the Nurse Practice Act and in
11 accordance with Section 303.05, a written delegation, and a
12 written collaborative agreement under Section 65-35 of the
13 Nurse Practice Act, an advanced practice registered nurse
14 certified as a nurse practitioner, nurse midwife, or clinical
15 nurse specialist who has been granted authority to prescribe by
16 a hospital affiliate in accordance with Section 65-45 of the
17 Nurse Practice Act and in accordance with Section 303.05, or an
18 advanced practice registered nurse certified as a nurse
19 practitioner, nurse midwife, or clinical nurse specialist who
20 has full practice authority pursuant to Section 65-43 of the
21 Nurse Practice Act.

22 (nn) "Prescription" means a written, facsimile, or oral
23 order, or an electronic order that complies with applicable
24 federal requirements, of a physician licensed to practice
25 medicine in all its branches, dentist, podiatric physician or
26 veterinarian for any controlled substance, of an optometrist in

1 accordance with Section 15.1 of the Illinois Optometric
2 Practice Act of 1987, of a prescribing psychologist licensed
3 under Section 4.2 of the Clinical Psychologist Licensing Act
4 with prescriptive authority delegated under Section 4.3 of the
5 Clinical Psychologist Licensing Act, of a physician assistant
6 for a controlled substance in accordance with Section 303.05, a
7 written delegation, and a written collaborative agreement
8 required under Section 7.5 of the Physician Assistant Practice
9 Act of 1987, of an advanced practice registered nurse with
10 prescriptive authority delegated under Section 65-40 of the
11 Nurse Practice Act who issues a prescription for a controlled
12 substance in accordance with Section 303.05, a written
13 delegation, and a written collaborative agreement under
14 Section 65-35 of the Nurse Practice Act, of an advanced
15 practice registered nurse certified as a nurse practitioner,
16 nurse midwife, or clinical nurse specialist who has been
17 granted authority to prescribe by a hospital affiliate in
18 accordance with Section 65-45 of the Nurse Practice Act and in
19 accordance with Section 303.05 when required by law, or of an
20 advanced practice registered nurse certified as a nurse
21 practitioner, nurse midwife, or clinical nurse specialist who
22 has full practice authority pursuant to Section 65-43 of the
23 Nurse Practice Act.

24 (nn-5) "Prescription Information Library" (PIL) means an
25 electronic library that contains reported controlled substance
26 data.

1 (nn-10) "Prescription Monitoring Program" (PMP) means the
2 entity that collects, tracks, and stores reported data on
3 controlled substances and select drugs pursuant to Section 316.

4 (oo) "Production" or "produce" means manufacture,
5 planting, cultivating, growing, or harvesting of a controlled
6 substance other than methamphetamine.

7 (pp) "Registrant" means every person who is required to
8 register under Section 302 of this Act.

9 (qq) "Registry number" means the number assigned to each
10 person authorized to handle controlled substances under the
11 laws of the United States and of this State.

12 (qq-5) "Secretary" means, as the context requires, either
13 the Secretary of the Department or the Secretary of the
14 Department of Financial and Professional Regulation, and the
15 Secretary's designated agents.

16 (rr) "State" includes the State of Illinois and any state,
17 district, commonwealth, territory, insular possession thereof,
18 and any area subject to the legal authority of the United
19 States of America.

20 (rr-5) "Stimulant" means any drug that (i) causes an
21 overall excitation of central nervous system functions, (ii)
22 causes impaired consciousness and awareness, and (iii) can be
23 habit-forming or lead to a substance abuse problem, including
24 but not limited to amphetamines and their analogs,
25 methylphenidate and its analogs, cocaine, and phencyclidine
26 and its analogs.

1 (rr-10) "Synthetic drug" includes, but is not limited to,
2 any synthetic cannabinoids or piperazines or any synthetic
3 cathinones as provided for in Schedule I.

4 (ss) "Ultimate user" means a person who lawfully possesses
5 a controlled substance for his or her own use or for the use of
6 a member of his or her household or for administering to an
7 animal owned by him or her or by a member of his or her
8 household.

9 (Source: P.A. 99-78, eff. 7-20-15; 99-173, eff. 7-29-15;
10 99-371, eff. 1-1-16; 99-480, eff. 9-9-15; 99-642, eff. 7-28-16;
11 100-280, eff. 1-1-18; 100-453, eff. 8-25-17; 100-513, eff.
12 1-1-18; revised 10-6-17.)

13 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

14 Sec. 204. (a) The controlled substances listed in this
15 Section are included in Schedule I.

16 (b) Unless specifically excepted or unless listed in
17 another schedule, any of the following opiates, including their
18 isomers, esters, ethers, salts, and salts of isomers, esters,
19 and ethers, whenever the existence of such isomers, esters,
20 ethers and salts is possible within the specific chemical
21 designation:

22 (1) Acetylmethadol;

23 (1.1) Acetyl-alpha-methylfentanyl

24 (N-[1-(1-methyl-2-phenethyl)-

25 4-piperidiny]]-N-phenylacetamide);

1 (2) Allylprodine;

2 (3) Alphacetylmethadol, except

3 levo-alphacetylmethadol (also known as levo-alpha-
4 acetylmethadol, levomethadyl acetate, or LAAM);

5 (4) Alphameprodine;

6 (5) Alphamethadol;

7 (6) Alpha-methylfentanyl

8 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
9 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
10 propanilido) piperidine;

11 (6.1) Alpha-methylthiofentanyl

12 (N-[1-methyl-2-(2-thienyl)ethyl-
13 4-piperidinyl]-N-phenylpropanamide);

14 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);

15 (7.1) PEPAP

16 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);

17 (8) Benzethidine;

18 (9) Betacetylmethadol;

19 (9.1) Beta-hydroxyfentanyl

20 (N-[1-(2-hydroxy-2-phenethyl)-
21 4-piperidinyl]-N-phenylpropanamide);

22 (10) Betameprodine;

23 (11) Betamethadol;

24 (12) Betaprodine;

25 (13) Clonitazene;

26 (14) Dextromoramide;

- 1 (15) Diampromide;
- 2 (16) Diethylthiambutene;
- 3 (17) Difenoquin;
- 4 (18) Dimenoxadol;
- 5 (19) Dimepseptanol;
- 6 (20) Dimethylthiambutene;
- 7 (21) Dioxaphetylbutyrate;
- 8 (22) Dipipanone;
- 9 (23) Ethylmethylthiambutene;
- 10 (24) Etonitazene;
- 11 (25) Etoperidine;
- 12 (26) Furethidine;
- 13 (27) Hydroxypethidine;
- 14 (28) Ketobemidone;
- 15 (29) Levomoramide;
- 16 (30) Levophenacetylmorphine;
- 17 (31) 3-Methylfentanyl
- 18 (N-[3-methyl-1-(2-phenylethyl)-
- 19 4-piperidyl]-N-phenylpropanamide);
- 20 (31.1) 3-Methylthiofentanyl
- 21 (N-[(3-methyl-1-(2-thienyl)ethyl-
- 22 4-piperidinyl]-N-phenylpropanamide);
- 23 (32) Morpheridine;
- 24 (33) Noracymethadol;
- 25 (34) Norlevorphanol;
- 26 (35) Normethadone;

1 (36) Norpipanone;
2 (36.1) Para-fluorofentanyl
3 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
4 4-piperidinyl]propanamide);
5 (37) Phenadoxone;
6 (38) Phenampromide;
7 (39) Phenomorphan;
8 (40) Phenoperidine;
9 (41) Piritramide;
10 (42) Proheptazine;
11 (43) Properidine;
12 (44) Propiram;
13 (45) Racemoramide;
14 (45.1) Thiofentanyl
15 (N-phenyl-N-[1-(2-thienyl)ethyl-
16 4-piperidinyl]-propanamide);
17 (46) Tilidine;
18 (47) Trimeperidine;
19 (48) Beta-hydroxy-3-methylfentanyl (other name:
20 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
21 N-phenylpropanamide);
22 (49) Furanyl fentanyl (FU-F);
23 (50) Butyryl fentanyl;
24 (51) Valeryl fentanyl;
25 (52) Acetyl fentanyl;
26 (53) Beta-hydroxy-thiofentanyl;

1 (54) 3,4-dichloro-N-[2-
2 (dimethylamino)cyclohexyl]-N-
3 methylbenzamide (U-47700);

4 (55) 4-chloro-N-[1-[2-
5 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
6 benzenesulfonamide (W-18);

7 (56) 4-chloro-N-[1-(2-phenylethyl)
8 -2-piperidinylidene]-benzenesulfonamide (W-15);

9 (57) acrylfentanyl (acryloylfentanyl).

10 (c) Unless specifically excepted or unless listed in
11 another schedule, any of the following opium derivatives, its
12 salts, isomers and salts of isomers, whenever the existence of
13 such salts, isomers and salts of isomers is possible within the
14 specific chemical designation:

15 (1) Acetorphine;

16 (2) Acetyldihydrocodeine;

17 (3) Benzylmorphine;

18 (4) Codeine methylbromide;

19 (5) Codeine-N-Oxide;

20 (6) Cyprenorphine;

21 (7) Desomorphine;

22 (8) Diacetyldihydromorphine (Dihydroheroin);

23 (9) Dihydromorphine;

24 (10) Drotebanol;

25 (11) Etorphine (except hydrochloride salt);

26 (12) Heroin;

- 1 (13) Hydromorphenol;
- 2 (14) Methyldesorphine;
- 3 (15) Methyldihydromorphine;
- 4 (16) Morphine methylbromide;
- 5 (17) Morphine methylsulfonate;
- 6 (18) Morphine-N-Oxide;
- 7 (19) Myrophine;
- 8 (20) Nicocodeine;
- 9 (21) Nicomorphine;
- 10 (22) Normorphine;
- 11 (23) Pholcodine;
- 12 (24) Thebacon.

13 (d) Unless specifically excepted or unless listed in
14 another schedule, any material, compound, mixture, or
15 preparation which contains any quantity of the following
16 hallucinogenic substances, or which contains any of its salts,
17 isomers and salts of isomers, whenever the existence of such
18 salts, isomers, and salts of isomers is possible within the
19 specific chemical designation (for the purposes of this
20 paragraph only, the term "isomer" includes the optical,
21 position and geometric isomers):

- 22 (1) 3,4-methylenedioxyamphetamine
- 23 (alpha-methyl, 3,4-methylenedioxyphenethylamine,
- 24 methylenedioxyamphetamine, MDA);

- 25 (1.1) Alpha-ethyltryptamine
- 26 (some trade or other names: etryptamine;

1 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
2 3-(2-aminobutyl)indole; a-ET; and AET);
3 (2) 3,4-methylenedioxymethamphetamine (MDMA);
4 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
5 (also known as: N-ethyl-alpha-methyl-
6 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
7 and MDEA);
8 (2.2) N-Benzylpiperazine (BZP);
9 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
10 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
11 (4) 3,4,5-trimethoxyamphetamine (TMA);
12 (5) (Blank);
13 (6) Diethyltryptamine (DET);
14 (7) Dimethyltryptamine (DMT);
15 (7.1) 5-Methoxy-diallyltryptamine;
16 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
17 (9) Ibogaine (some trade and other names:
18 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
19 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
20 indole; Tabernanthe iboga);
21 (10) Lysergic acid diethylamide;
22 (10.1) Salvinorin A;
23 (10.5) Salvia divinorum (meaning all parts of the plant
24 presently classified botanically as Salvia divinorum,
25 whether growing or not, the seeds thereof, any extract from
26 any part of that plant, and every compound, manufacture,

1 salts, isomers, and salts of isomers whenever the existence
2 of such salts, isomers, and salts of isomers is possible
3 within the specific chemical designation, derivative,
4 mixture, or preparation of that plant, its seeds or
5 extracts);

6 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

7 (12) Peyote (meaning all parts of the plant presently
8 classified botanically as *Lophophora williamsii* Lemaire,
9 whether growing or not, the seeds thereof, any extract from
10 any part of that plant, and every compound, manufacture,
11 salts, derivative, mixture, or preparation of that plant,
12 its seeds or extracts);

13 (13) N-ethyl-3-piperidyl benzilate (JB 318);

14 (14) N-methyl-3-piperidyl benzilate;

15 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
16 (also known as N-hydroxy-alpha-methyl-
17 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

18 (15) Parahexyl; some trade or other names:
19 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
20 dibenzo (b,d) pyran; Synhexyl;

21 (16) Psilocybin;

22 (17) Psilocyn;

23 (18) Alpha-methyltryptamine (AMT);

24 (19) 2,5-dimethoxyamphetamine
25 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

26 (20) 4-bromo-2,5-dimethoxyamphetamine

1 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

2 4-bromo-2,5-DMA);

3 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

4 Some trade or other names: 2-(4-bromo-

5 2,5-dimethoxyphenyl)-1-aminoethane;

6 alpha-desmethyl DOB, 2CB, Nexus;

7 (21) 4-methoxyamphetamine

8 (4-methoxy-alpha-methylphenethylamine;

9 paramethoxyamphetamine; PMA);

10 (22) (Blank);

11 (23) Ethylamine analog of phencyclidine.

12 Some trade or other names:

13 N-ethyl-1-phenylcyclohexylamine,

14 (1-phenylcyclohexyl) ethylamine,

15 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

16 (24) Pyrrolidine analog of phencyclidine. Some trade

17 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,

18 PHP;

19 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

20 (26) 2,5-dimethoxy-4-ethylamphetamine

21 (another name: DOET);

22 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

23 (another name: TCPy);

24 (28) (Blank);

25 (29) Thiophene analog of phencyclidine (some trade

26 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

2-thienyl analog of phencyclidine; TCP; TCP);

(29.1) Benzothiophene analog of phencyclidine. Some trade or other names: BTCP or benocyclidine;

(29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

(30) Bufotenine (some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; 5-hydroxy-N,N-dimethyltryptamine; N,N-dimethylserotonin; mappine);

(31) (Blank);

(32) (Blank);

(33) (Blank);

(34) (Blank);

(34.5) (Blank);

(35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
Some trade or other names: HU-210;

(35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol, its isomers, salts, and salts of isomers; Some trade or other names: HU-210, Dexanabinol;

(36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

1 Some trade or other names: HU-211;

2 (37) (Blank);

3 (38) (Blank);

4 (39) (Blank);

5 (40) (Blank);

6 (41) (Blank);

7 (42) Any compound structurally derived from
8 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane
9 by substitution at the nitrogen atom of the indole ring by
10 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
11 cycloalkylethyl, aryl halide, alkyl aryl halide,
12 1-(N-methyl-2-piperidiny)lmethyl, or
13 2-(4-morpholinyl)ethyl whether or not further substituted
14 in the indole ring to any extent, whether or not
15 substituted in the naphthyl ring to any extent. Examples of
16 this structural class include, but are not limited to,
17 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;

18 (43) Any compound structurally derived from
19 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
20 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22 halide, 1-(N-methyl-2-piperidiny)lmethyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 in the pyrrole ring to any extent, whether or not
25 substituted in the naphthyl ring to any extent. Examples of
26 this structural class include, but are not limited to,

1 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

2 (44) Any compound structurally derived from
3 1-(1-naphthylmethyl)indene by substitution at the
4 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6 halide, 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl whether or not further substituted
8 in the indene ring to any extent, whether or not
9 substituted in the naphthyl ring to any extent. Examples of
10 this structural class include, but are not limited to,
11 JWH-176;

12 (45) Any compound structurally derived from
13 3-phenylacetylindole by substitution at the nitrogen atom
14 of the indole ring with alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 in the indole ring to any extent, whether or not
19 substituted in the phenyl ring to any extent. Examples of
20 this structural class include, but are not limited to,
21 JWH-167, JWH-250, JWH-251, and RCS-8;

22 (46) Any compound structurally derived from
23 2-(3-hydroxycyclohexyl)phenol by substitution at the
24 5-position of the phenolic ring by alkyl, haloalkyl,
25 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
26 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not substituted in the
2 cyclohexyl ring to any extent. Examples of this structural
3 class include, but are not limited to, CP 47, 497 and its
4 C8 homologue (cannabicyclohexanol);

5 (46.1) Any compound structurally derived from
6 3-(benzoyl) indole with substitution at the nitrogen atom
7 of the indole ring by an alkyl, haloalkyl, alkenyl,
8 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
9 halide, 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl group whether or not further
11 substituted in the indole ring to any extent and whether or
12 not substituted in the phenyl ring to any extent. Examples
13 of this structural class include, but are not limited to,
14 AM-630, AM-2233, AM-694, Pravadolone (WIN 48,098), and
15 RCS-4;

16 (47) (Blank);

17 (48) (Blank);

18 (49) (Blank);

19 (50) (Blank);

20 (51) (Blank);

21 (52) (Blank);

22 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine_
23 Some trade or other names: 2C-T-7;

24 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine_
25 or other names: 2C-E;

26 (53.2) 2,5-dimethoxy-4-methylphenethylamine_
Some

1 trade or other names: 2C-D;

2 (53.3) 4-chloro-2,5-dimethoxyphenethylamine_ Some
3 trade or other names: 2C-C;

4 (53.4) 4-iodo-2,5-dimethoxyphenethylamine_ Some trade
5 or other names: 2C-I;

6 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine_ Some
7 trade or other names: 2C-T-2;

8 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine_
9 Some trade or other names: 2C-T-4;

10 (53.7) 2,5-dimethoxyphenethylamine_ Some trade or
11 other names: 2C-H;

12 (53.8) 2,5-dimethoxy-4-nitrophenethylamine_ Some trade
13 or other names: 2C-N;

14 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine_ Some
15 trade or other names: 2C-P;

16 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine_ Some
17 trade or other names: 2C-G;

18 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
19 phenethylamine referred to in subparagraphs (20.1), (53),
20 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
21 (53.8), (53.9), and (53.10) including, but not limited to,
22 25I-NBOMe and 25C-NBOMe;

23 (54) 5-Methoxy-N,N-diisopropyltryptamine;

24 (55) (Blank);

25 (56) (Blank);

26 (57) (Blank);

1 (58) (Blank);

2 (59) 3-cyclopropoylindole with substitution at the
3 nitrogen atom of the indole ring by alkyl, haloalkyl,
4 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
5 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indole ring to any extent, whether or not
8 substituted on the cyclopropyl ring to any extent:
9 including, but not limited to, XLR11, UR144, FUB-144;

10 (60) 3-adamantoylindole with substitution at the
11 nitrogen atom of the indole ring by alkyl, haloalkyl,
12 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
13 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
14 2-(4-morpholinyl)ethyl, whether or not further substituted
15 on the indole ring to any extent, whether or not
16 substituted on the adamantyl ring to any extent: including,
17 but not limited to, AB-001;

18 (61) N-(adamantyl)-indole-3-carboxamide with
19 substitution at the nitrogen atom of the indole ring by
20 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
21 cycloalkylethyl, aryl halide, alkyl aryl halide,
22 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indole ring to any extent, whether or not
25 substituted on the adamantyl ring to any extent: including,
26 but not limited to, APICA/2NE-1, STS-135;

1 (62) N-(adamantyl)-indazole-3-carboxamide with
2 substitution at a nitrogen atom of the indazole ring by
3 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
4 cycloalkylethyl, aryl halide, alkyl aryl halide,
5 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the indazole ring to any extent, whether or not
8 substituted on the adamantyl ring to any extent: including,
9 but not limited to, AKB48, 5F-AKB48;

10 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
11 with substitution at the nitrogen atom of the indole ring
12 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
13 cycloalkylethyl, aryl halide, alkyl aryl halide,
14 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the indole ring to any extent, whether or not
17 substituted on the quinoline ring to any extent: including,
18 but not limited to, PB22, 5F-PB22, FUB-PB-22;

19 (64) 3-(1-naphthoyl)indazole with substitution at the
20 nitrogen atom of the indazole ring by alkyl, haloalkyl,
21 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
22 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indazole ring to any extent, whether or not
25 substituted on the naphthyl ring to any extent: including,
26 but not limited to, THJ-018, THJ-2201;

1 (65) 2-(1-naphthoyl)benzimidazole with substitution at
2 the nitrogen atom of the benzimidazole ring by alkyl,
3 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
4 aryl halide, alkyl aryl halide,
5 1-(N-methyl-2-piperidinyl)methyl, or
6 2-(4-morpholinyl)ethyl, whether or not further substituted
7 on the benzimidazole ring to any extent, whether or not
8 substituted on the naphthyl ring to any extent: including,
9 but not limited to, FUBIMINA;

10 (66) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
11 3-carboxamide with substitution on the nitrogen atom of the
12 indazole ring by alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14 halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the indazole ring to any extent: including, but not
17 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;

18 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
19 indazole-3-carboxamide with substitution on the nitrogen
20 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indazole ring to any extent: including, but not
25 limited to, ADB-PINACA, ADB-FUBINACA;

26 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-

1 indole-3-carboxamide with substitution on the nitrogen
2 atom of the indole ring by alkyl, haloalkyl, alkenyl,
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further substituted
6 on the indole ring to any extent: including, but not
7 limited to, ADBICA, 5F-ADBICA;

8 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
9 3-carboxamide with substitution on the nitrogen atom of the
10 indole ring by alkyl, haloalkyl, alkenyl,
11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
12 halide, 1-(N-methyl-2-piperidinyl)methyl, or
13 2-(4-morpholinyl)ethyl, whether or not further substituted
14 on the indole ring to any extent: including, but not
15 limited to, ABICA, 5F-ABICA;

16 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
17 methylbutanoate with substitution on the nitrogen atom of
18 the indazole ring by alkyl, haloalkyl, alkenyl,
19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
20 halide, 1-(N-methyl-2-piperidinyl)methyl, or
21 2-(4-morpholinyl)ethyl, whether or not further substituted
22 on the indazole ring to any extent: including, but not
23 limited to, AMB, 5F-AMB;

24 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
25 dimethylbutanoate with substitution on the nitrogen atom
26 of the indazole ring by alkyl, haloalkyl, alkenyl,

1 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
2 halide, 1-(N-methyl-2-piperidinyl)methyl, or
3 2-(4-morpholinyl)ethyl, whether or not further substituted
4 on the indazole ring to any extent: including, but not
5 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;

6 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
7 methylbutanoate with substitution on the nitrogen atom of
8 the indole ring by alkyl, haloalkyl, alkenyl,
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl, whether or not further substituted
12 on the indazole ring to any extent: including, but not
13 limited to, MMB018, MMB2201, and AMB-CHMICA;

14 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
15 dimethylbutanoate with substitution on the nitrogen atom
16 of the indole ring by alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 on the indazole ring to any extent: including, but not
21 limited to, MDMB-CHMICA;

22 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
23 indazole-3-carboxamide with substitution on the nitrogen
24 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26 halide, 1-(N-methyl-2-piperidinyl)methyl, or

1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indazole ring to any extent: including, but not
3 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;

4 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
5 3-carboxamide with substitution on the nitrogen atom of the
6 indole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indazole ring to any extent: including, but not
11 limited to, APP-PICA and 5-fluoro-APP-PICA;

12 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
13 4-AcO-DMT;

14 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
15 name 5-MeO-MIPT;

16 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);

17 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

18 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DIPT);

19 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
20 (4-HO-MIPT);

21 (82) Fluorophenylpiperazine;

22 (83) Methoxetamine;

23 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
24 ethcathinone).

25 (e) Unless specifically excepted or unless listed in
26 another schedule, any material, compound, mixture, or

1 preparation which contains any quantity of the following
2 substances having a depressant effect on the central nervous
3 system, including its salts, isomers, and salts of isomers
4 whenever the existence of such salts, isomers, and salts of
5 isomers is possible within the specific chemical designation:

6 (1) mecloqualone;

7 (2) methaqualone; and

8 (3) gamma hydroxybutyric acid.

9 (f) Unless specifically excepted or unless listed in
10 another schedule, any material, compound, mixture, or
11 preparation which contains any quantity of the following
12 substances having a stimulant effect on the central nervous
13 system, including its salts, isomers, and salts of isomers:

14 (1) Fenethylline;

15 (2) N-ethylamphetamine;

16 (3) Aminorex (some other names:

17 2-amino-5-phenyl-2-oxazoline; aminoxaphen;

18 4-5-dihydro-5-phenyl-2-oxazamine) and its

19 salts, optical isomers, and salts of optical isomers;

20 (4) Methcathinone (some other names:

21 2-methylamino-1-phenylpropan-1-one;

22 Ephedrone; 2-(methylamino)-propionophenone;

23 alpha-(methylamino)propionophenone; N-methylcathinone;

24 methycathinone; Monomethylpropion; UR 1431) and its

25 salts, optical isomers, and salts of optical isomers;

26 (5) Cathinone (some trade or other names:

1 2-aminopropiophenone; alpha-aminopropiophenone;

2 2-amino-1-phenyl-propanone; norephedrone);

3 (6) N,N-dimethylamphetamine (also known as:

4 N,N-alpha-trimethyl-benzeneethanamine;

5 N,N-alpha-trimethylphenethylamine);

6 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
7 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazoline);

8 (8) 3,4-Methylenedioxypyrovalerone (MDPV);

9 (9) Halogenated amphetamines and
10 methamphetamines - any compound derived from either
11 amphetamine or methamphetamine through the substitution
12 of a halogen on the phenyl ring, including, but not
13 limited to, 2-fluoroamphetamine, 3-
14 fluoroamphetamine and 4-fluoroamphetamine;

15 (10) Aminopropylbenzofuran (APB):
16 including 4-(2-Aminopropyl) benzofuran, 5-
17 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
18 benzofuran, and 7-(2-Aminopropyl) benzofuran;

19 (11) Aminopropyldihydrobenzofuran (APDB):
20 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
21 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
22 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
23 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

24 (12) Methylaminopropylbenzofuran
25 (MAPB): including 4-(2-methylaminopropyl)
26 benzofuran, 5-(2-methylaminopropyl)benzofuran,

1 6-(2-methylaminopropyl)benzofuran
2 and 7-(2-methylaminopropyl)benzofuran.

3 (g) Temporary listing of substances subject to emergency
4 scheduling. Any material, compound, mixture, or preparation
5 that contains any quantity of the following substances:

6 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
7 (benzylfentanyl), its optical isomers, isomers, salts, and
8 salts of isomers;

9 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
10 phenylpropanamide (thenylfentanyl), its optical isomers,
11 salts, and salts of isomers.

12 (h) Synthetic cathinones. Unless specifically excepted,
13 any chemical compound which is not approved by the United
14 States Food and Drug Administration or, if approved, is not
15 dispensed or possessed in accordance with State or federal law,
16 not including bupropion, structurally derived from
17 2-aminopropan-1-one by substitution at the 1-position with
18 either phenyl, naphthyl, or thiophene ring systems, whether or
19 not the compound is further modified in one or more of the
20 following ways:

21 (1) by substitution in the ring system to any extent
22 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
23 halide substituents, whether or not further substituted in
24 the ring system by one or more other univalent
25 substituents. Examples of this class include, but are not
26 limited to, 3,4-Methylenedioxycathinone (bk-MDA);

1 (2) by substitution at the 3-position with an acyclic
2 alkyl substituent. Examples of this class include, but are
3 not limited to, 2-methylamino-1-phenylbutan-1-one
4 (buphedrone); or

5 (3) by substitution at the 2-amino nitrogen atom with
6 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
7 inclusion of the 2-amino nitrogen atom in a cyclic
8 structure. Examples of this class include, but are not
9 limited to, Dimethylcathinone, Ethcathinone, and
10 a-Pyrrolidinopropiophenone (a-PPP); ~~or-~~

11 Any other synthetic cathinone which is not approved by the
12 United States Food and Drug Administration or, if approved, is
13 not dispensed or possessed in accordance with State or federal
14 law.

15 (i) Synthetic cannabinoids or piperazines. Any synthetic
16 cannabinoid or piperazine which is not approved by the United
17 States Food and Drug Administration or, if approved, which is
18 not dispensed or possessed in accordance with State and federal
19 law.

20 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
21 100-368, eff. 1-1-18; revised 10-5-17.)".